Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project KR Carson, AM Evens, EA Richey, TM Habermann, D Focosi, JF Seymour, ... Blood, The Journal of the American Society of Hematology 113 (20), 4834-4840, 2009 | 1053 | 2009 |
Genetic and functional drivers of diffuse large B cell lymphoma A Reddy, J Zhang, NS Davis, AB Moffitt, CL Love, A Waldrop, S Leppa, ... Cell 171 (2), 481-494. e15, 2017 | 1008 | 2017 |
The genetic landscape of mutations in Burkitt lymphoma C Love, Z Sun, D Jima, G Li, J Zhang, R Miles, KL Richards, CH Dunphy, ... Nature genetics 44 (12), 1321-1325, 2012 | 679 | 2012 |
Genetic heterogeneity of diffuse large B-cell lymphoma J Zhang, V Grubor, CL Love, A Banerjee, KL Richards, PA Mieczkowski, ... Proceedings of the National Academy of Sciences 110 (4), 1398-1403, 2013 | 630 | 2013 |
Pure red-cell aplasia and epoetin therapy CL Bennett, S Luminari, AR Nissenson, MS Tallman, SA Klinge, ... New England Journal of Medicine 351 (14), 1403-1408, 2004 | 553 | 2004 |
Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis AM Petrich, M Gandhi, B Jovanovic, JJ Castillo, S Rajguru, DT Yang, ... Blood, The Journal of the American Society of Hematology 124 (15), 2354-2361, 2014 | 526 | 2014 |
An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas M Agulnik, JL Yarber, SH Okuno, M Von Mehren, BD Jovanovic, ... Annals of Oncology 24 (1), 257-263, 2013 | 403 | 2013 |
Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports AM Evens, BD Jovanovic, YC Su, DW Raisch, D Ganger, SM Belknap, ... Annals of Oncology 22 (5), 1170-1180, 2011 | 403 | 2011 |
Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era AM Evens, KA David, I Helenowski, B Nelson, D Kaufman, SM Kircher, ... Journal of Clinical Oncology 28 (6), 1038, 2010 | 349 | 2010 |
Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies Z Al-Mansour, BP Nelson, AM Evens Current hematologic malignancy reports 8, 173-183, 2013 | 313 | 2013 |
US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose–positron emission tomography imaging: Southwest … OW Press, H Li, H Schöder, DJ Straus, CH Moskowitz, M LeBlanc, ... Journal of Clinical Oncology 34 (17), 2020, 2016 | 301 | 2016 |
T-cell non-Hodgkin lymphoma MA Rizvi, AM Evens, MS Tallman, BP Nelson, ST Rosen Blood 107 (4), 1255-1264, 2006 | 275 | 2006 |
Oxidative stress and apoptosis: a new treatment paradigm in cancer RH Engel, AM Evens Front Biosci 11 (1), 300-312, 2006 | 269 | 2006 |
Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs DD Jima, J Zhang, C Jacobs, KL Richards, CH Dunphy, WWL Choi, ... Blood, The Journal of the American Society of Hematology 116 (23), e118-e127, 2010 | 264 | 2010 |
Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole S Trifilio, S Singhal, S Williams, O Frankfurt, L Gordon, A Evens, J Winter, ... Bone marrow transplantation 40 (5), 451-456, 2007 | 255 | 2007 |
Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy SM Trifilio, CL Bennett, PR Yarnold, JM McKoy, J Parada, J Mehta, ... Bone marrow transplantation 39 (7), 425-429, 2007 | 252 | 2007 |
The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future AM Evens, MS Tallman, RB Gartenhaus Leukemia research 28 (9), 891-900, 2004 | 245 | 2004 |
Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients S Trifilio, G Pennick, J Pi, J Zook, M Golf, K Kaniecki, S Singhal, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2007 | 234 | 2007 |
Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience AR Mato, C Nabhan, PM Barr, CS Ujjani, BT Hill, N Lamanna, ... Blood, The Journal of the American Society of Hematology 128 (18), 2199-2205, 2016 | 217 | 2016 |
Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the … CC Tigue, JM McKoy, AM Evens, SM Trifilio, MS Tallman, CL Bennett Bone marrow transplantation 40 (3), 185-192, 2007 | 210 | 2007 |